Post-ASH 2025 Multiple Myeloma Highlights

Featuring presentations & discussions on selected myeloma abstracts from the 67^th ASH Annual Meeting and Exposition

Tuesday 27 January | 08:00 – 10:00 CST/ 14:00 – 16:00 GMT/ 15:00 – 17:00 CET

Chair: Doris Hansen | Moderators: Nisha Joseph and Salomon Manier

Register Now

Preliminary Agenda:

Welcome and introductions 

Session 1: Updates in risk stratification and response-adapted management  in myeloma and monoclonal gammopathies

Results of the promise study from ~30,000 individuals screened for monoclonal gammopathies (ABSTRACT ID abs25-10090; ABSTRACT ID 403) | Speaker: Sabine Allam

Redefining function high-risk (FHR) multiple myeloma (MM) in the context of upfront quadruplet (QUAD) therapy and autologous stem cell transplantation (ASCT) (ABSTRACT ID abs25-2422; ABSTRACT ID 1037) | Speaker: TBC

Characterization of NDMM patients treated with daratumumab, lenalidomide, bortezomib and dexamethasone who fail to achieve a VGPR or have early progression (ABSTRACT ID abs25-14135; ABSTRACT ID 407) | Speaker: Jonathan Kaufman

Panel Discussion

Session 2: Latest evidence with small molecule therapies  

Randomized phase II dose optimization study of inobrodib (CCS1477), in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma (RRMM) (ABSTRACT ID abs25-4306; ABSTRACT ID 4035) | Speaker: Nisha Joseph

Iberdomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: An update from the phase 2 EMN26 trial 
(ABSTRACT ID abs25-4452; ABSTRACT ID 101) | Speaker: TBC

Panel Discussion

Session 3: Advances with CAR T-cell therapy in myeloma 

Safety and efficacy of AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy, in relapsed/refractory multiple myeloma: Preliminary Results from the DURGA-1 Phase 1b/2 study (ABSTRACT ID abs25-11319; ABSTRACT ID 269) | Speaker: Shambavi Richard

Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma: Updated results from iMMagine—1 (ABSTRACT ID abs25-4541; ABSTRACT ID 256) | Speaker: Krina Patel

Enhancing the safety of ciltacabtagene autoleucel in relapsed multiple myeloma (MM): Identification of potentially modifiable risk-factors associated with delayed neurotoxicity and non-relapse mortality (ABSTRACT ID abs25-2357; ABSTRACT ID 1034) | Speaker: Surbhi Sidana 

Predictors of early relapse following ciltacabtagene autoleucel: Informing risk-adapted therapy in relapsed/refractory multiple myeloma 
(ABSTRACT ID abs25-15365; ABSTRACT ID 93) | Speaker: Doris Hansen

Efficacy and safety of frail adults treated with ciltacabtagene autoleucel in the real-world: A CIBMTR analysis (ABSTRACT ID abs25-4065; ABSTRACT ID 133) | Speaker: Hira Mian

Panel Discussion

Session 4: Recent progress with T-cell engagers in treatment naïve and R/R myeloma

A phase 2 study of teclistamab in combination with daratumumab in elderly patients with newly diagnosed multiple myeloma: The IFM2021-01 teclille trial, cohort A (ABSTRACT ID abs25-10098; ABSTRACT ID 367) | Speaker: Salomon Manier 

Phase 2 study of cevostamab consolidation following BCMA CAR T cell therapy:  preliminary safety, efficacy, and correlative data from the “STEM” (Sequential T Cell-Engagement for Myeloma) trial (ABSTRACT ID abs25-7733; ABSTRACT ID 699) | Speaker: Adam Cohen

Initial results of the first-in-human Phase 1 study of IBI3003, a novel trispecific antibody targeting GPRC5D, BCMA and CD3, in patients with relapsed or refractory multiple myeloma (ABSTRACT ID abs25-10881; ABSTRACT ID 702) | Speaker: TBC

Safety and efficacy of linvoseltamab (LINVO) combined with anti-CD38 monoclonalantibodies (mAbs) daratumumab (DARA) or isatuximab (ISA) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial results from the multicohort, Phase 1b LINKER-MM2 trial  (ABSTRACT ID abs25-2230; ABSTRACT ID 2254) | Speaker: TBC

Updated efficacy and safety results of JNJ-5322, a novel, next-generation BCMA×GPRC5D×CD3 trispecific antibody, in patients with Relapsed/Refractory multiple myeloma (ABSTRACT ID abs25-7875; ABSTRACT ID 4042) | Speaker: Amrita Krishnan

Panel Discussion

Conclusions and meeting close